Poster (Scientific congresses and symposiums)
Pneumocystis jirovecii pneumonia in IBD patients treated with immunomodulator(s)
VIEUJEAN, Sophie; MOENS, Annick; ROTHFUSS, Katja et al.
201914th Congress of ECCO
Peer reviewed
 

Files


Full Text
Pneumocystis jirovecii_ECCO 2019.pdf
Publisher postprint (233.21 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
pneumocystis jiroveci; Inflammatory bowel disease
Abstract :
[en] Background: Pneumocystis jirovecii Pneumonia (PJP) is an extremely rare life-threatening pulmonary fungal infection that occurs in immunocompromised individuals including patients with inflammatory bowel disease (IBD). Prophylaxis for PJP is recommended in IBD patients treated with triple immunomodulators where one agent is a calcineurin inhibitor or an anti-TNFα1 but there is no consistency in a preventive approach in patients with double or single immunomodulators. Our aim was to describe immunosuppressive treatment profile of IBD patients infected by PJP and the outcome of the disease. Methods: Cases of PJP were retrospectively collected through the COllaborative Network For Exceptionally Rare case reports of the European Crohn’s and Colitis Organization (ECCO CONFER). All ECCO members were invited to report cases of PJP. Data were collected through a case report form. Results: A total of 15 PJP infections were reported in 14 IBD patients (9 ulcerative colitis and 5 Crohn’s disease including 10 men and 4 women). The median age at PJP diagnosis was 55 years (IQR 44-80). Diagnosis was performed by a positive PJ polymerase chain reaction on the bronchoalveolar lavage in 87% of the cases and by a microscopic direct exam in 7% (unreported in 1 patient). One patient was co-infected by HIV and 57% were non-smokers. Immunosuppressive therapies at the time of diagnosis included steroids (n=11), thiopurines (n=9), infliximab (n=3), cyclosporin (n=2), methotrexate (n=1) and tacrolimus (n=1). Two PJP (13%) occurred in patients on triple immunosuppression, 9 patients (60 %) had a double immunosuppressive treatment, 3 patients (20%) were on monotherapy and PJP in the HIV patient occurred in absence of immunosuppressive treatment (Table 1). None of the patients diagnosed with PJP had received prophylaxis. All patients were treated by trimethoprim/sulfamethoxazole or atovaquone and 5 required an intensive care unit stay. Two patients (14%) died and 1 patient had a recurrent episode 16 months after initial treatment. Evolution was favourable for the others. Conclusion: This small case series reports PJP in IBD patients while on single or double immunosuppression highlighting a significant risk in this population. Identifying risk factors for PJP infection in the IBD population is essential to provide a case-by-case prophylaxis.
Disciplines :
General & internal medicine
Author, co-author :
VIEUJEAN, Sophie  ;  Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de gastroentérologie, hépatologie, onco. digestive
MOENS, Annick;  University Hospitals Leuven, Leuven, Belgium > Department of Gastroenterology and Hepatology
ROTHFUSS, Katja;  Robert-Bosch-Hospital, Stuttgart, Germany > Department of Gastroenterology and Hepatology
SAVARINO, Edoardo;  University of Padua, Padua, Italy > Department of Gastroenterology
VAVRICKA, Stephan;  University Hospital, Zurich, Switzerland > Department of Gastroenterology and Hepatology,
REENAERS, Catherine ;  University Hospital of Liège, Liège, Belgium > Department of Gastroenterology
FERRANTE, Marc;  University Hospitals Leuven, Leuven, Belgium > Department of Gastroenterology and Hepatology
RAHIER, Jean-François;  CHU UCL Namur, Yvoir, Belgium > Department of Gastroenterology and Hepatology
Language :
English
Title :
Pneumocystis jirovecii pneumonia in IBD patients treated with immunomodulator(s)
Publication date :
February 2019
Event name :
14th Congress of ECCO
Event date :
du 6 mars 2019 au 9 mars 2019
Audience :
International
Peer reviewed :
Peer reviewed
Available on ORBi :
since 26 May 2019

Statistics


Number of views
60 (8 by ULiège)
Number of downloads
27 (2 by ULiège)

Bibliography


Similar publications



Contact ORBi